Fred Hutch's Value in Cancer Care conference, held November 6, focused on patient and provider burnout; the growing data ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

Viral immunologist Paul Thomas, PhD, is working to turn the “incredible potential” of the immune system into real-life diagnostic and therapeutic applications that will improve vaccination strategies ...

Philanthropy fuels Fred Hutch’s breakthroughs. Our community's support drives life-changing discoveries, strengthens patient and caregiver experiences, and helps build the next generation of ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...

In this conversation, Petros Grivas, MD, PhD, discusses his new podcast aimed at exploring the latest developments in cancer care and research. He emphasizes the importance of learning from colleagues ...